Abstract

The localization and characterization of tumor suppressor genes has profound implications for prevention and treatment of cancer. The primary goal of this research is to develop statistical tools to expedite the search for tumor suppressor gene candidates.
The specific aims of this research are: to develop statistical significance tests that will help identify tumor suppressor gene candidates from loss of heterozygosity studies and deletion mapping studies; to provide methods for determining whether allelic loss patterns from different groups of patients are significantly different; to produce publicly available software for implementing these procedures; and to estimate biologically important characteristics of the allelic loss process in neoplastic progression. The methods for achieving these aims will involve the formulation of models for genetic events in tumorigenesis, focusing primarily on allelic loss events. Power studies will be performed which will allow scientists to determine the sample sizes to achieve various levels of certainty in the identification of tumor suppressor gene candidates.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA077607-02
Application #
2896450
Study Section
Special Emphasis Panel (ZRG7-STA (01))
Program Officer
Seminara, Daniela
Project Start
1998-04-01
Project End
2003-03-31
Budget Start
1999-04-01
Budget End
2000-03-31
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost

  Institution

Name
University of Washington
Department
Biostatistics & Other Math Sci
Type
Schools of Public Health
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195

  Publications

Jardine, David; Cornel, Leanne; Emond, Mary (2011) Gene expression analysis characterizes antemortem stress and has implications for establishing cause of death. Physiol Genomics 43:974-80
Bronner, Mary P; O'Sullivan, Jacintha N; Rabinovitch, Peter S et al. (2008) Genomic biomarkers to improve ulcerative colitis neoplasia surveillance. Am J Pathol 173:1853-60
Wallden, Brett; Emond, Mary; Swift, Mari E et al. (2005) Antimetastatic gene expression profiles mediated by retinoic acid receptor beta 2 in MDA-MB-435 breast cancer cells. BMC Cancer 5:140
Hoff, Peter D (2005) Subset clustering of binary sequences, with an application to genomic abnormality data. Biometrics 61:1027-36
Swanson, Cristina; Saintigny, Yannick; Emond, Mary J et al. (2004) The Werner syndrome protein has separable recombination and survival functions. DNA Repair (Amst) 3:475-82
Desai, Manisha; Emond, Mary J (2004) A new mixture model approach to analyzing allelic-loss data using Bayes factors. BMC Bioinformatics 5:182
Colgin, Lorel M; Hackmann, Alden F M; Emond, Mary J et al. (2002) The unexpected landscape of in vivo somatic mutation in a human epithelial cell lineage. Proc Natl Acad Sci U S A 99:1437-42
Treutin, Piper M; Chen, Lucinda I; Buetow, Bernard S et al. (2002) Retinoic acid receptor beta2 inhibition of metastasis in mouse mammary gland xenografts. Breast Cancer Res Treat 72:79-88
Prince, P R; Emond, M J; Monnat Jr, R J (2001) Loss of Werner syndrome protein function promotes aberrant mitotic recombination. Genes Dev 15:933-8
Moser, M J; Bigbee, W L; Grant, S G et al. (2000) Genetic instability and hematologic disease risk in Werner syndrome patients and heterozygotes. Cancer Res 60:2492-6

Showing the most recent 10 out of 11 publications